KR102123287B1 - 면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 - Google Patents
면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 Download PDFInfo
- Publication number
- KR102123287B1 KR102123287B1 KR1020180135752A KR20180135752A KR102123287B1 KR 102123287 B1 KR102123287 B1 KR 102123287B1 KR 1020180135752 A KR1020180135752 A KR 1020180135752A KR 20180135752 A KR20180135752 A KR 20180135752A KR 102123287 B1 KR102123287 B1 KR 102123287B1
- Authority
- KR
- South Korea
- Prior art keywords
- saliva
- adrenal cortical
- cortisol
- quantifying
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003296 saliva Anatomy 0.000 title claims abstract description 77
- 229920000742 Cotton Polymers 0.000 title claims abstract description 31
- 230000001919 adrenal effect Effects 0.000 title description 3
- 150000003431 steroids Chemical class 0.000 title description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000003470 adrenal cortex hormone Substances 0.000 claims abstract description 50
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 40
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 28
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 28
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960004544 cortisone Drugs 0.000 claims abstract description 28
- 239000002243 precursor Substances 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 16
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 13
- 238000000132 electrospray ionisation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 238000004811 liquid chromatography Methods 0.000 claims description 9
- 239000000186 progesterone Substances 0.000 claims description 9
- 229960003387 progesterone Drugs 0.000 claims description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 8
- 235000019253 formic acid Nutrition 0.000 claims description 8
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 8
- 102000053187 Glucuronidase Human genes 0.000 claims description 7
- 108010060309 Glucuronidase Proteins 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000001886 cortisols Chemical class 0.000 claims description 7
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 7
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000009834 vaporization Methods 0.000 claims description 4
- 230000008016 vaporization Effects 0.000 claims description 4
- JYGXADMDTFJGBT-LTVXCZLVSA-N (8s,10r,11s,13s)-9,11,12,12-tetradeuterio-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)C3([2H])[C@@]([2H])(O)C([2H])([2H])[C@]4(C)C(O)(C(=O)CO)CCC4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-LTVXCZLVSA-N 0.000 claims description 3
- RJKFOVLPORLFTN-PQIPVKAESA-N (8s,9s,10r,13s,14s,17s)-2,2,4,6,6,17-hexadeuterio-10,13-dimethyl-17-(2,2,2-trideuterioacetyl)-7,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@]1(C)[C@@]([2H])(C(=O)C([2H])([2H])[2H])CC[C@H]1[C@@H]1CC2([2H])[2H])C[C@@H]1[C@]1(C)C2=C([2H])C(=O)C([2H])([2H])C1 RJKFOVLPORLFTN-PQIPVKAESA-N 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 150000003146 progesterones Chemical class 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 230000002503 metabolic effect Effects 0.000 abstract description 12
- 229940088597 hormone Drugs 0.000 abstract description 10
- 239000005556 hormone Substances 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 3
- 230000001054 cortical effect Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract description 2
- 230000037323 metabolic rate Effects 0.000 description 11
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 8
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 6
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 3
- 238000000752 ionisation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001423 neocortical effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
- HESFZGWRDUVOMS-FJNAKSJRSA-N 18-Hydroxycortisol Chemical compound C([C@]1(CO)[C@](O)(C(=O)CO)CC[C@H]1[C@@H]1CC2)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 HESFZGWRDUVOMS-FJNAKSJRSA-N 0.000 description 1
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000020576 Adrenal disease Diseases 0.000 description 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003131 corticotrophic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G01N30/724—Nebulising, aerosol formation or ionisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/067—Preparation by reaction, e.g. derivatising the sample
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/665—Assays involving proteins derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- G01N2333/695—Corticotropin [ACTH]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
도 2는 본 발명을 통하여 면봉으로부터 채취된 타액 내 코르티솔(F)과 코르티손(E)의 대사비율(F/E)을 평가한 것으로서, 쿠싱질환과 정상인과의 차이(A) 및 쿠싱질환 환자의 수술 전후의 변화(B)를 도식화 한 그래프이다.
분석물질 | 정상인 | 쿠싱질환 | ||
기존타액키트 (ng/mL) |
면봉 (pg) |
기존타액키트 (ng/mL) |
면봉 (pg) |
|
코르티솔(F) | 3.87±1.62 | 584±125 | 31.11±16.14 | 5378±1208 |
코르티손(E) | 12.32±4.93 | 1029±367 | 31.83±16.66 | 3247±644 |
F/E | 0.36±0.18 | 1.93±4.09 | 0.51±0.74 | 0.66±1.08 |
분석물질 | 수술 전 (pg) |
수술 직후 (pg) |
progesterone | 637±118 | 848±484 |
20a-hydroxycortisol | 842±172 | 160±39 |
18-hydroxycortisol | 114±46 | 55±10 |
tetrahydrocortisol | 4378±442 | 1911±413 |
21-deoxycortisol | 191±113 | 178±22 |
cortisol (F) | 4724±1116 | 1529±288 |
cortisone (E) | 3038±337 | 929±277 |
F/E | 0.63±0.99 | 1.26±1.24 |
Claims (10)
- 타액 내 부신피질호르몬을 정량하는 방법에 있어서,
(a) 면봉을 이용하되, 면봉을 입안에 1분 이하로 머무르게 하여 타액을 채취하는 단계,
(b) 타액을 효소 가수분해 하는 단계,
(c) 가수분해된 타액을 메탄올 용매를 사용한 고체상 추출법을 통해 용출시켜 추출하는 단계, 및
(d) 상기 추출된 시료를 유기용매로 재용해하여 액체 크로마토그래피-질량분석법으로 전기분무이온화(electrospray ionization, ESI)방식으로 분석하는 단계를 포함하며,
상기 전기분무이온화에서 사용하는 질수 분무가스의 유량은 2.0 L/min 내지 3.0 L/min 이며, 기화 온도는 250℃ 내지 350℃ 이고, capillary 전압은 3.0 kV 내지 5.0 kV 이고,
상기 (d)의 액체 크로마토그래피의 이동상은 5% 아세토니트릴(acetonitrile)과 0.1% 포름산(formic acid)을 포함한 수용액 (A)과, 0.1% 포름산(formic acid)을 포함한 95% 아세토니트릴 수용액(B)의 농도 구배가 형성된 것을 사용하며, 유속은 0.20 ㎖/min 내지 0.30 ㎖/min 으로 유지시키는 것을 특징으로 하는,
타액 내 부신피질호르몬을 정량하는 방법.
- 삭제
- 제 1 항에 있어서,
상기 (a) 단계에서 타액을 묻힌 면봉은 가수분해 전 분석의 대상이 된 부신피질호르몬의 내부표준물질과 혼합하는 단계를 포함하는, 타액 내 부신피질호르몬을 정량하는 방법.
- 제1항에 있어서,
상기 (b)의 효소 가수분해는 베타-글루쿠로니다아제(β-glucuronidase)를 이용하여 가수분해 하는 것인, 타액 내 부신피질호르몬을 정량하는 방법.
- 삭제
- 삭제
- 제1항에 있어서,
상기 (d)의 액체 크로마토그래피의 컬럼은 길이가 40 내지 60 mm 이고, 내경은 1 내지 3 mm 이며, 충전물 입자의 크기는 1.0 μm 내지 3.0 μm 인, 타액 내 부신피질호르몬을 정량하는 방법.
- 삭제
- 제 1항에 있어서,
상기 (d)의 액체 크로마토그래피의 농도 구배 조건은 A : B = 90 : 10 (v/v)에서 5분까지 B가 25% 되도록 한 다음, 8분까지 B가 60%, 14분까지 B를 100%, 18분까지 B를 초기 조성인 10%가 되도록 회귀한 다음, 10분 동안 B를 10%의 조성으로 유지시키는 것을 특징으로 하는, 타액 내 부신피질호르몬을 정량하는 방법.
- 제 3항에 있어서,
상기 내부표준물질은 프로게스테론에 대해서는 중수소 치환 프로게스테론(progesterone-2,2,4,6,6,17α,21,21,21-d 9 ),
코르티솔과 코르티손, 그리고 코르티솔의 전구체 및 대사체에 대해서는 중수소 치환 코르티솔(cortisol-9,11,12,12-d 4 ),을 사용하는 것을 특징으로 하는, 타액 내 부신피질호르몬을 정량하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180135752A KR102123287B1 (ko) | 2018-11-07 | 2018-11-07 | 면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 |
US16/395,069 US11360105B2 (en) | 2018-11-07 | 2019-04-25 | Method of evaluating adrenal steroids in saliva collected by cotton swab |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180135752A KR102123287B1 (ko) | 2018-11-07 | 2018-11-07 | 면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200052601A KR20200052601A (ko) | 2020-05-15 |
KR102123287B1 true KR102123287B1 (ko) | 2020-06-17 |
Family
ID=70459499
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180135752A Active KR102123287B1 (ko) | 2018-11-07 | 2018-11-07 | 면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 |
Country Status (2)
Country | Link |
---|---|
US (1) | US11360105B2 (ko) |
KR (1) | KR102123287B1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160231341A1 (en) * | 2015-02-05 | 2016-08-11 | Castle Medical, LLC | Multidrug analysis in urine by liquid chromatography-tandem mass spectrometry |
US20160349221A1 (en) | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101029251B1 (ko) | 2009-06-18 | 2011-04-18 | 전남대학교산학협력단 | 타액내 코티졸 측정을 통한 코티졸의 일주기리듬 평가 지표 및 방법 |
KR101152902B1 (ko) * | 2010-10-05 | 2012-06-07 | 한국과학기술연구원 | 정량적인 스테로이드 인식 기술을 이용한 머리카락 시료 간 대사 차별성 평가 방법 |
KR101228322B1 (ko) * | 2010-12-29 | 2013-01-31 | 재단법인 서울의과학연구소 | 타액 중의 스테로이드 호르몬의 정량 방법 |
EP3042208A4 (en) | 2013-09-06 | 2017-04-19 | Theranos, Inc. | Systems and methods for detecting infectious diseases |
-
2018
- 2018-11-07 KR KR1020180135752A patent/KR102123287B1/ko active Active
-
2019
- 2019-04-25 US US16/395,069 patent/US11360105B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160231341A1 (en) * | 2015-02-05 | 2016-08-11 | Castle Medical, LLC | Multidrug analysis in urine by liquid chromatography-tandem mass spectrometry |
US20160349221A1 (en) | 2015-05-27 | 2016-12-01 | Quest Diagnostics Investments Llc | Methods for mass spectrometric quantitation of analytes extracted from a microsampling device |
JP2018515796A (ja) | 2015-05-27 | 2018-06-14 | クエスト ダイアグノスティックス インヴェストメンツ エルエルシー | マイクロサンプリングデバイスにより抽出された被分析物の質量分析による定量のための方法 |
Also Published As
Publication number | Publication date |
---|---|
US11360105B2 (en) | 2022-06-14 |
KR20200052601A (ko) | 2020-05-15 |
US20200141952A1 (en) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McWhinney et al. | Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11-deoxycortisol with ultra high performance liquid chromatography–tandem mass spectrometry: application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory | |
Spyridaki et al. | Doping control analysis in human urine by liquid chromatography–electrospray ionization ion trap mass spectrometry for the Olympic Games Athens 2004: Determination of corticosteroids and quantification of ephedrines, salbutamol and morphine | |
Büttler et al. | Testosterone, androstenedione, cortisol and cortisone levels in human unstimulated, stimulated and parotid saliva | |
Kataoka et al. | Simultaneous determination of testosterone, cortisol, and dehydroepiandrosterone in saliva by stable isotope dilution on-line in-tube solid-phase microextraction coupled with liquid chromatography–tandem mass spectrometry | |
KR101228322B1 (ko) | 타액 중의 스테로이드 호르몬의 정량 방법 | |
US20110281369A1 (en) | Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry | |
Kicman et al. | Proposed confirmatory procedure for detecting 5 alpha-dihydrotestosterone doping in male athletes | |
Elio et al. | Human saliva cortisone and cortisol simultaneous analysis using reverse phase HPLC technique | |
Bui et al. | Salivary testosterone in female-to-male transgender adolescents during treatment with intra-muscular injectable testosterone esters | |
Honour | Steroid profiling | |
Sánchez-Guijo et al. | Determination of free cortisol and free cortisone in human urine by on-line turbulent flow chromatography coupled to fused-core chromatography–tandem mass spectrometry (TFC–HPLC–MS/MS) | |
Godage et al. | Biocompatible SPME fibers for direct monitoring of nicotine and its metabolites at ultra trace concentration in rabbit plasma following the application of smoking cessation formulations | |
Ahi et al. | Simultaneous identification of prednisolone and its ten metabolites in human urine by high performance liquid chromatography‐tandem mass spectrometry | |
Alvi et al. | An improved method for measurement of testosterone in human plasma and saliva by ultra-performance liquid chromatography-tandem mass spectrometry | |
Koskivuori et al. | A quantitative ultra-performance liquid chromatography high-resolution mass spectrometry analysis of steroids from human scalp hair | |
Vanaelst et al. | Measurement of cortisol and cortisone in children's hair using ultra performance liquid chromatography and tandem mass spectrometry | |
KR102123287B1 (ko) | 면봉으로 채취된 타액 내 부신피질호르몬 평가 방법 | |
CN110702829A (zh) | 一种测定血浆或血清中醛固酮含量的方法 | |
Pommier et al. | Simultaneous determination of imipramine and its metabolite desipramine in human plasma by capillary gas chromatography with mass-selective detection | |
US20180348176A1 (en) | Stress biomarkers and related non-invasive detection methods | |
US20020064883A1 (en) | Measurement and quantification of 17 ketosteroid-sulfates as a biomarker of biological age | |
Cho et al. | Rapid column‐switching liquid chromatography/mass spectrometric assay for DHEA‐sulfate in the plasma of patients with Alzheimer's disease | |
CN108020625A (zh) | 血浆中花生四烯酸乙醇胺和2-花生四烯甘油含量的检测方法及先兆流产诊断试剂盒 | |
Weiermair et al. | Implementation and validation of a UHPLC-MS/MS method for quantification of the endocannabinoids AEA and 2-AG in cerebral interstitial fluid and plasma | |
JP2023547378A (ja) | ヒト血漿中のリゼルギン酸ジエチルアミド(lsd)及び2,3-ジヒドロ-3-ヒドロキシ-2-オキソリセルギド(o-h-lsd)を定量化するための方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20181107 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200107 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200429 |
|
PG1501 | Laying open of application | ||
PN2301 | Change of applicant |
Patent event date: 20200604 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200610 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20200611 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20230523 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20240527 Start annual number: 5 End annual number: 5 |